Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Grafton shares drop on trading slowdown, cautious outlook

(Sharecast News) - Shares in Grafton Group dropped on Thursday after the builders merchant said it experienced a slowdown in trading activity towards the end of the first half, with markets expected to "remain challenging" over the rest of the year. Group revenues totalled £1.25bn over the six months to 30 June, up 10.1% over the previous year, helped by recent acquisitions of Salvador Escoda in Spain and HSS Hire Ireland.

Excluding those, daily like-for-like revenues were up 2.4% on last year.

"Trading activity recovered strongly after a subdued start to the year however there was a slow down in momentum from mid-May and into June as a spike in geopolitical uncertainty appeared to dent consumer confidence in the period," said chief executive Eric Born.

He said the company remains uncertain about the timing of a market recovery, especially in the UK and Finlan where conditions are still challenging.

As a result, Grafton doesn't expect to increase volumes this year, but said that it is actively managing margins and the cost base.

"Despite macroeconomic uncertainty, the medium-term outlook for Grafton remains positive, supported by housing shortages across all our markets and an anticipated recovery in RMI demand. We continue to invest in and strengthen our market positions supported by a robust balance sheet and strong cash flow generation," the company said.

The stock was down nearly 8% at 917p by 0955 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.